This is a deliberate update to the existing comparison between AMBOSS AI Mode and OpenEvidence, and to the broader look at how each company's 2026 expansion strategy differs. Rather than re-deriving the full comparison already covered in both of those pieces, this update covers specifically what has changed since: AMBOSS's EHR integration roadmap and OpenEvidence's enterprise patient-data partnerships, both genuinely new developments worth adding to the existing picture.
AMBOSS's integration roadmap, in brief
AMBOSS's stated three-phase plan, covered in full detail elsewhere in this content series, moves from live in-chart search today, without patient data, towards planned patient-context analysis, and eventually towards structured suggestions written back into the record for clinician review. As of the time of writing, only the first phase is actually live.
OpenEvidence's enterprise direction, in brief
OpenEvidence has moved considerably further and faster along a similar underlying path, through direct enterprise partnerships rather than a self-built roadmap alone. It has already established enterprise, EHR-embedded access with Sutter Health and Mount Sinai, and on 20 May 2026 announced a partnership with Cedars-Sinai Health System specifically framed around what OpenEvidence calls patient-aware clinical intelligence: integrating patient context directly from Epic, so that a clinician's natural-language question is answered in the context of that specific patient's allergies, comorbidities, medications and prior procedures, rather than as a generic query. Cedars-Sinai has been described as the first academic health system to deploy this specific patient-aware capability at enterprise scale, joining Mount Sinai and Sutter Health as enterprise partners.
Comparing source philosophies, briefly restated
AMBOSS's bounded, clinician-curated corpus and OpenEvidence's broader literature and publisher-partnership model remain as different as they were before this update, and that underlying philosophical difference, covered at length in the existing comparison this article updates, has not changed.
Comparing personalisation, the genuinely new axis
What has changed is the degree and route to personalisation each platform now offers. AMBOSS offers specialty-aware responses today, tailoring depth and framing to a clinician's own specialty, but has not yet reached genuine patient-specific personalisation in its live product. OpenEvidence has moved directly to patient-aware enterprise intelligence, at least within its enterprise partner health systems, reading the actual patient's record to shape its answer, a materially more advanced stage of personalisation than AMBOSS currently offers in production.
Comparing workflow ambitions
AMBOSS is moving from chart access towards eventual action, still working through its own internal roadmap. OpenEvidence is moving from search towards agentic record interpretation considerably faster, having already reached enterprise-scale deployment of patient-context reading through direct health-system partnerships rather than a slower, purely internal build.
The principal safety question this update raises directly
Does greater patient context genuinely improve clinical recommendations enough to justify the additional governance risk it introduces. This is not a question either company's own announcements can answer on their own; it requires the kind of independent evaluation this content series has consistently called for, applied specifically to patient-aware systems where the stakes of getting it wrong are measurably higher than for a generic, non-patient-specific answer.
Where iatroX remains positioned
iatroX's position relative to both platforms is unchanged by this update: a UK and EU national-guidance alternative, competing on jurisdiction-specific relevance rather than on the size of its literature corpus or the speed of its enterprise patient-data rollout. Neither AMBOSS's roadmap nor OpenEvidence's Cedars-Sinai partnership currently addresses UK-specific guidance, and this update does not change that underlying picture.
A balanced conclusion, updated
OpenEvidence has moved further, faster, on patient-aware integration specifically, through direct enterprise health-system partnerships. AMBOSS continues to build a comparable capability more incrementally, alongside a genuinely strong safety showing in the NOHARM benchmark covered elsewhere in this series. Which matters more to a given clinician or institution depends on whether patient-aware personalisation or curated-source safety is the more pressing current priority, and that trade-off remains genuinely unresolved rather than settled by either company's most recent announcement.